| Autor: |
Patel, Shyam Ajay, Gerber, William K, Zheng, Rena, Khanna, Shrinkhala, Hutchinson, Lloyd, Cerny, Jan, Dasilva, Brandon, Zhang, Tian Y., Khedr, Salwa, Selove, William, Woda, Bruce, Abel, Gregory A, Miron, Patricia Minehart, Higgins, Anne, Gerber, Jonathan M. |
| Zdroj: |
Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p4068-4068, 1p |
| Abstrakt: |
Background:Clonal hematopoiesis of indeterminate potential (CHIP) is a clinically defined entity that is recognized by the 2022 International Consensus Classification and the 5 thEdition of the WHO. While the Clonal Hematopoiesis Risk Score (CHRS) incorporates 8 variables that underlie a prognostic framework for prediction of risk for progression to myeloid neoplasm (MN) (Weeks LD et al., NEJM Evidence2023), there remains debate as to the role of mutations in epigenetic regulators, such as DNMT3A, TET2and ASXL1(“DTA”), with respect to clinical outcomes in the real-world setting. Although DTA mutations often occur early in myeloid pathogenesis, the persistence of these mutations as age-related clonal hematopoiesis (CH) might not significantly influence clinical course (Jongen-Lavrencic M et al., NEJM2018). We have previously observed impaired clearance of DTA-mutant clones with hypomethylating agent or intensive chemotherapy for myelodysplastic neoplasms and acute myeloid leukemia (ASH abstract 4122; Blood(2022) 140 (Supplement 1): 9150-9151), and we now seek to understand the impact of sole DTA mutations in patients with CH. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
